
FDMT Stock Forecast & Price Target
FDMT Analyst Ratings
Bulls say
4D Molecular Therapeutics Inc has demonstrated notable efficacy in its ophthalmology product candidates, specifically with positive clinical trial results showing significant gains in Best-Corrected Visual Acuity (BCVA) and reductions in injection burden among recently diagnosed patients. The company boasts a strong financial position with an extended cash runway of $505 million projected to last into 2028, which is expected to facilitate the advancement of pivotal studies. Furthermore, 4D Molecular Therapeutics is strategically aligning its research focus to target high-need areas within ophthalmology and cystic fibrosis, indicating a commitment to sustainable growth and enhanced shareholder value through innovative gene therapy solutions.
Bears say
4D Molecular Therapeutics exhibits a negative outlook due to significant net losses, amounting to $161 million for 2024, which reflects an unsustainable operational model given its non-revenue generating status. Furthermore, the company faces potential downward revisions to its valuation if early-stage trial results are not replicated in later phases, or if new safety concerns arise within its product pipeline. Compounding these issues, 4D's limited manufacturing capacity and complexities inherent in AAV-based gene therapy could lead to delays in product development and commercialization, adding further uncertainty to its financial projections.
This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
FDMT Analyst Forecast & Price Prediction
Start investing in FDMT
Order type
Buy in
Order amount
Est. shares
0 shares